Cargando…

Low-Frequency versus High-Frequency Ultrasound-Mediated Transdermal Delivery of Agomelatine-Loaded Invasomes: Development, Optimization and in-vivo Pharmacokinetic Assessment

AIM: Agomelatine (AGM) is the first melatonergic antidepressant. It suffers from low oral bioavailability (<5%) due to extensive hepatic metabolism. The current work aimed to develop an alternative AGM-loaded invasomes to enhance transdermal drug bioavailability. METHODOLOGY: AGM-loaded invasomes...

Descripción completa

Detalles Bibliográficos
Autores principales: Tawfik, Mai Ahmed, Tadros, Mina Ibrahim, Mohamed, Magdy Ibrahim, Nageeb El-Helaly, Sara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7669507/
https://www.ncbi.nlm.nih.gov/pubmed/33209023
http://dx.doi.org/10.2147/IJN.S283911
_version_ 1783610586733477888
author Tawfik, Mai Ahmed
Tadros, Mina Ibrahim
Mohamed, Magdy Ibrahim
Nageeb El-Helaly, Sara
author_facet Tawfik, Mai Ahmed
Tadros, Mina Ibrahim
Mohamed, Magdy Ibrahim
Nageeb El-Helaly, Sara
author_sort Tawfik, Mai Ahmed
collection PubMed
description AIM: Agomelatine (AGM) is the first melatonergic antidepressant. It suffers from low oral bioavailability (<5%) due to extensive hepatic metabolism. The current work aimed to develop an alternative AGM-loaded invasomes to enhance transdermal drug bioavailability. METHODOLOGY: AGM-loaded invasomes were developed using two drug: lipid ratios (1:10 or 1:7.5), four terpene types (limonene, cineole, fenchone or citral) and two terpene concentrations (0.75% or 1.5%, w/v). They were characterized for drug entrapment efficiency (EE%), particle size (PS), zeta potential (ZP) and drug released percentages after 0.5h (Q(0.5h)) and 8h (Q(8h)). The optimum invasomes (I1, I2 and I4) were evaluated for morphology, drug-crystallinity, and ex-vivo drug flux. The variables influencing sonophoresis of the best achieved invasomal gel system (I2) were optimized including, ultrasound frequency (low, LFU or high, HFU), mode (pulsed or continuous), application period (10 min or 15 min) and duty cycle (50% or 100%). AGM pharmacokinetics were evaluated in rabbits following transdermal application of I2-LFU-C4 system, relative to AGM oral dispersion. RESULTS: The superiority of I2 invasomes [comprising AGM and phosphatidylcholine (1:10) and limonene (1.5% w/v)] was statistically revealed with respect to EE% (78.6%), PS (313 nm), ZP (−64 mV), Q(0.5h) (30.1%), Q(8h) (92%), flux (10.79 µg/cm2/h) and enhancement ratio (4.83). The optimum sonophoresis conditions involved application of LFU in the continuous mode for 15 min at a 100% duty cycle (I2-LFU-C4 system). The latter system showed significantly higher C(max), and relative bioavailability (≈ 7.25 folds) and a similar T(max) (0.5 h). CONCLUSION: I2-LFU-C4 is a promising transdermal system for AGM.
format Online
Article
Text
id pubmed-7669507
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-76695072020-11-17 Low-Frequency versus High-Frequency Ultrasound-Mediated Transdermal Delivery of Agomelatine-Loaded Invasomes: Development, Optimization and in-vivo Pharmacokinetic Assessment Tawfik, Mai Ahmed Tadros, Mina Ibrahim Mohamed, Magdy Ibrahim Nageeb El-Helaly, Sara Int J Nanomedicine Original Research AIM: Agomelatine (AGM) is the first melatonergic antidepressant. It suffers from low oral bioavailability (<5%) due to extensive hepatic metabolism. The current work aimed to develop an alternative AGM-loaded invasomes to enhance transdermal drug bioavailability. METHODOLOGY: AGM-loaded invasomes were developed using two drug: lipid ratios (1:10 or 1:7.5), four terpene types (limonene, cineole, fenchone or citral) and two terpene concentrations (0.75% or 1.5%, w/v). They were characterized for drug entrapment efficiency (EE%), particle size (PS), zeta potential (ZP) and drug released percentages after 0.5h (Q(0.5h)) and 8h (Q(8h)). The optimum invasomes (I1, I2 and I4) were evaluated for morphology, drug-crystallinity, and ex-vivo drug flux. The variables influencing sonophoresis of the best achieved invasomal gel system (I2) were optimized including, ultrasound frequency (low, LFU or high, HFU), mode (pulsed or continuous), application period (10 min or 15 min) and duty cycle (50% or 100%). AGM pharmacokinetics were evaluated in rabbits following transdermal application of I2-LFU-C4 system, relative to AGM oral dispersion. RESULTS: The superiority of I2 invasomes [comprising AGM and phosphatidylcholine (1:10) and limonene (1.5% w/v)] was statistically revealed with respect to EE% (78.6%), PS (313 nm), ZP (−64 mV), Q(0.5h) (30.1%), Q(8h) (92%), flux (10.79 µg/cm2/h) and enhancement ratio (4.83). The optimum sonophoresis conditions involved application of LFU in the continuous mode for 15 min at a 100% duty cycle (I2-LFU-C4 system). The latter system showed significantly higher C(max), and relative bioavailability (≈ 7.25 folds) and a similar T(max) (0.5 h). CONCLUSION: I2-LFU-C4 is a promising transdermal system for AGM. Dove 2020-11-12 /pmc/articles/PMC7669507/ /pubmed/33209023 http://dx.doi.org/10.2147/IJN.S283911 Text en © 2020 Tawfik et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Tawfik, Mai Ahmed
Tadros, Mina Ibrahim
Mohamed, Magdy Ibrahim
Nageeb El-Helaly, Sara
Low-Frequency versus High-Frequency Ultrasound-Mediated Transdermal Delivery of Agomelatine-Loaded Invasomes: Development, Optimization and in-vivo Pharmacokinetic Assessment
title Low-Frequency versus High-Frequency Ultrasound-Mediated Transdermal Delivery of Agomelatine-Loaded Invasomes: Development, Optimization and in-vivo Pharmacokinetic Assessment
title_full Low-Frequency versus High-Frequency Ultrasound-Mediated Transdermal Delivery of Agomelatine-Loaded Invasomes: Development, Optimization and in-vivo Pharmacokinetic Assessment
title_fullStr Low-Frequency versus High-Frequency Ultrasound-Mediated Transdermal Delivery of Agomelatine-Loaded Invasomes: Development, Optimization and in-vivo Pharmacokinetic Assessment
title_full_unstemmed Low-Frequency versus High-Frequency Ultrasound-Mediated Transdermal Delivery of Agomelatine-Loaded Invasomes: Development, Optimization and in-vivo Pharmacokinetic Assessment
title_short Low-Frequency versus High-Frequency Ultrasound-Mediated Transdermal Delivery of Agomelatine-Loaded Invasomes: Development, Optimization and in-vivo Pharmacokinetic Assessment
title_sort low-frequency versus high-frequency ultrasound-mediated transdermal delivery of agomelatine-loaded invasomes: development, optimization and in-vivo pharmacokinetic assessment
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7669507/
https://www.ncbi.nlm.nih.gov/pubmed/33209023
http://dx.doi.org/10.2147/IJN.S283911
work_keys_str_mv AT tawfikmaiahmed lowfrequencyversushighfrequencyultrasoundmediatedtransdermaldeliveryofagomelatineloadedinvasomesdevelopmentoptimizationandinvivopharmacokineticassessment
AT tadrosminaibrahim lowfrequencyversushighfrequencyultrasoundmediatedtransdermaldeliveryofagomelatineloadedinvasomesdevelopmentoptimizationandinvivopharmacokineticassessment
AT mohamedmagdyibrahim lowfrequencyversushighfrequencyultrasoundmediatedtransdermaldeliveryofagomelatineloadedinvasomesdevelopmentoptimizationandinvivopharmacokineticassessment
AT nageebelhelalysara lowfrequencyversushighfrequencyultrasoundmediatedtransdermaldeliveryofagomelatineloadedinvasomesdevelopmentoptimizationandinvivopharmacokineticassessment